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Abstract 
Introduction: The aim of this study was to explore the potential role of IL-35 in Graves’ disease (GD). 
Material and methods: A total of 142 GD patients including 80 newly onset patients, 52 refractory patients and 10 remission patients 
and 70 normal controls (NCs) were recruited. The messenger RNA (mRNA) expressions of P35 and Epstein-Barr-virus-induced gene 3 
(Ebi3) were measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Serum level of IL-35 was measured by 
enzyme-linked immunosorbent assay (ELISA).
Results: The expression of IL-35mRNA in new onset GD and refractory GD were both significantly higher than NC. Comparison between 
remission GD and NC showed no significant difference (p > 0.05). A significant increase of Ebi3mRNA expression was observed in new 
onset GD compared with remission GD (p = 0.030). The new onset GD showed a tendency for increased expression of serum IL-35 but 
without significant difference. No correlation between IL-35 expression and clinic parameters was found. 
Conclusions: Our preliminary observations indicate that IL-35 and CD4+P35+Ebi3+T cells may be involved in the pathogenesis of GD. 
(Endokrynol Pol 2019; 70 (4): 318–322)
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Introduction
Graves’ disease (GD) is classified as an organ-specific 
autoimmune disease and is also the most common 
cause of clinical hyperthyroidism. The classical triad 
of GD is thyrotoxicosis, goitre, and ophthalmopathy. 
Although its exact aetiology is still unknown, GD is 
generally believed to be caused by immune dysfunc-
tion, especially cellular immune dysfunction. Unbal-
anced CD4+T lymphocytes (CD4+T) and relevant 
cytokines are major contributors to its immunological 
pathogenesis. These include Th1 [1, 2], Th2 [1, 3], Th17 
[3–5] regulatory T cell (Treg) [4, 5], Th22 [6], and fol-
licular helper T cell (Tfh) [7, 8] and their correspond-
ing cytokine profile interferon-g (IFN-g), interleukin-4 
(IL-4), interleukin-17 (IL-17), interleukin-10 (IL-10), 
transforming growth factor-b (TGF-b), interleukin-22 
(IL-22), interleukin-21(IL-21), etc.
Ineleukin-35, a new member of the IL-12 family, is 
a heterodimer formed by Epstein-Barr-virus-induced 
gene 3 (Ebi3) and P35 [9]. Human thymus-derived 
CD4+Treg (nTreg) can secret IL-35 inconsecutively [10]. 
Whereas, iTr35, a newly defined induced Treg (iTreg) 
can produce IL-35 consecutively [10]. Furthermore, 
a recent study found that regulatory B cell (Breg) can 
also secret IL-35 as well as IL-10 [11–13]. The receptor 
of IL-35 is a unique IL-12Rb2:gp130 heterodimer or 
IL-12Rb2:IL-12Rb2, gp130:gp130 homodimers. IL-35R 
signalling is mainly through transcription factors STAT1 
and STAT4, which can bind to the distinct sites of P35 
and Ebi3 promoters [14]. However, a study also found 
that the binding of IL-35 to an IL-12Rb2:WSX-1 het-
erodimer can induce the activation of STAT1 and STAT3 
in Breg [14].
In vivo, IL-35 can suppress immune response 
through the suppression of Th17 proliferation, IL-17 
secretion, and expansion of Treg [16]. The immu-
nosuppression function of IL-35 and iTr35 has been 
confirmed in multiple autoimmune diseases includ-
ing Hashimoto’s thyroiditis (HT) [17], systemic lupus 
erythematosus (SLE) [18], inflammatory bowel disease 
(IBD) [19], and multiple sclerosis (MS) [20] and in vari-
able animal models such as experimental autoimmune 
encephalomyelitis (EAE) [10] and collagen-induced 
arthritis (CIA) [21]. Despite these studies, the expression 
of IL-35 or IL-35-producing cells in GD is still not well 
understood. Therefore, the present study was initiated 
to analyse the expression of IL-35 and IL-35-producing 
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ated by the continuity correction in c2 test. For the unbalanced 
groups, covariance analysis was used. Differences between groups 
were compared using Mann-Whitney-U-test. Spearman correla-
tion test was used to assess the associations between IL-35 levels 
and clinical parameters. p < 0.05 was considered as statistically 
significant.
Results
The expression of P35mRNA and Ebi3mRNA 
were increased in GD patients
Thirty new onset GD, 22 refractory GD, 10 remis-
sion GD, and 30 age- and gender-matched NC were 
enrolled for qRT-PCR. The demographic and clinical 
data of the participants are shown in Table II. Com-
pared to the other three groups, the age of remission 
GD patients was relatively high and lacked balance 
between groups. Hence, the comparisons between 
remission GD and other groups were conducted 
using covariance analysis. As shown in Figure 1, the 
expression of P35mRNA and Ebi3mRNA in new on-
set GD and refractory GD were significantly higher 
than in NC. Comparison between remission GD 
and NC showed no significant difference (p > 0.05). 
A significant increase of Ebi3mRNA expression was 
observed in new onset GD compared with remission 
GD (p = 0.030). The expression of P35mRNA tended 
to be higher in new onset GD than remission GD 
but without significant difference (p > 0.05). Unfor-
tunately, spearman correlation analysis revealed no 
correlation between clinical parameters (FT3, FT4, 
TSH, and TRAb) and any kind of mRNA expression 
(p > 0.05).
The new onset GD showed a tendency 
for increased expression of serum IL-35
Serum from 30 new onset GD, 30 refractory GD, and 
20 age- and gender-matched NC were collected for 
ELISA. However, the positive rate of IL-35 in total 
samples was just approximately 30%. Demographic 
and clinical data of those subjects are shown in Table III. 
Serum IL-35 concentration among new onset GD 
cells in peripheral blood of GD patients and their cor-
relation with clinical features.
Material and methods
Study subjects
A total of 142 GD patients including 80 newly onset patients, 
52 refractory patients, and 10 remission patients were recruited 
randomly from the inpatient and outpatient department of endo-
crinology of Jinshan Hospital of Fudan University. Seventy normal 
controls (NCs) were recruited from the health check-up department 
of the same hospital. GD was defined by: 1) manifestations of hyper-
thyroidism, such as weight loss despite a hearty appetite, fatigue, 
irritability, anxiety, tremor, palpitations, and so on; 2) biochemical 
confirmation of hyperthyroidism including decreased serum 
thyrotropic-stimulating hormone (TSH), increased free triiodo-
thyronine (FT3) and/or free tetraiodothyronine (FT4), the positive 
circulation of thyrotropin receptor antibody (TRAb), or thyroid 
peroxidase antibodies (TPOAb) (normal range: TSH 0.27–4.2 mU/L, 
FT4 12–22 pmol/L, FT3 3.1–6.8 pmol/L, TRAb 0–1.75 IU/L, TPOAb 
0–34 IU/mL); 3) the presence of diffused enlarged thyroid gland; 
4) the presence of thyroid-associated ophthalmopathy (TAO); and 
5) the presence of dermopathy, which is often shown as pretibial 
myxoedema. The demographic and clinical characteristics, includ-
ing thyroid function parameters (FT3, FT4, TSH) and TRAb of each 
subject, were gathered.
Refractory GD was defined as those the discontinue antithyroid 
drugs (ATD) should be persistent for more than two years after 
initiation of the therapy and were still positive for TRAb [22]. Remis-
sion GD was defined as those who maintained a euthyroid status 
for more than one year after withdrawal of ATD [22].
Sample processing
Blood samples of each participant were collected into Vacutainer 
tubes containing ethylenediamine tetra-acetic acid (EDTA). PBMCs 
were isolated by Ficoll–Hypaque gradient and washed with 
phosphate-buffered saline (PBS) (Hyclone, USA). PBMCs were 
then resuspended with TRIzol reagent (Invitrogen, Bleiswijk, 
the Netherlands) to extract mRNA for quantitative real-time PCR 
(qRT-PCR). Fasting blood samples were clotted for 30 min at room 
temperature and then centrifuged at 3000 g for 10 min to collect 
serum specimens. All samples were stored at –80∞.
mRNA isolation and quantitative real-time PCR
Total mRNAs were isolated from PBMCs with TRIzol reagent. The 
quantity and purity of mRNAs were measured by the absorbance on 
an Epoch Multi-Volume Spectrophotometer System (Biotek, USA) 
at 260 nm and 280 nm. MRNA samples with A260/A280 between 
1.8 and 2.0 were then reverse transcribed using a PrimeScript RT 
reagent Kit (TaKaRa, Japan) following the commercially available 
protocol. The cDNA samples were stored at –20∞ for next analysis. 
As for qRT-PCR, the ABI PRISM 7300 Fast Real-Time PCR system 
(BIO-RAD) with SYBR Premix Ex TaqTM II (Perfect Real Time) 
(TaKaRa, Japan) were used according with the manufacturers’ 
guidelines. Gene expressions were normalised by b-actin. The 
primer sequences of P35, Ebi3, and b-actin are listed in Table  I. 
The amplification and melting curves were checked after reaction.
Enzyme-linked immunosorbent assay
Serum IL-35 levels were measured using commercially available 
sandwich enzyme-linked immunosorbent assay (ELISA) (Bioleg-
end, USA) in strict accordance with the manufacturers’ protocols.
Statistical analysis
All statistical analyses were conducted using SPSS 17.0. Data were 
expressed as the mean ± SD. Balance between groups was evalu-
Table I. Sequences for qRT-PCR primers
Gene Primer sequences Product (bp)
P35
Forward:5’- TCCTCCCTTGAAGAACCGGA-3’
148
Reverse:5’- TGACAACGGTTTGGAGGGAC-3’
Ebi3
Forward:5’- AGCCACGTCCTTCATCCTC-3’
138
Reverse:5’- TACTTGCCCAGGCTCATTGT-3’
b-actin
Forward:5’- CATTGCCGACAGGATGCAG-3’
169
Reverse:5’- CTCGTCATACTCCTGCTTGCTG-3’
qRT-PCR — quantitative reverse transcription polymerase chain reaction
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(8.43 ± 5.88 ng/mL), refractory GD (7.40 ± 4.66 ng/mL) 
and NC (5.75 ± 4.27 ng/ml) had no statistical differ-
ence (p > 0.05), but there was an increasing tendency 
in new onset GD compared with NC. No correlation 
was found between IL-35 concentration and clinical 
parameters (p > 0.05) (Fig. 2).
Table II. Demographic and clinical data of participants — participants for qRT-PCR
Characteristics New onset GD Refractory GD Remission GD NC
Gender
Male 6 3 5 10
Female 24 19 5 20
Age [years] 33.8 ± 10.2 34.1 ± 11.8 50.9 ± 7.52 33.0 ± 9.91
Thyroid function
FT3 [pmol/L] 30.4 ± 12.0 6.68 ± 4.44 4.52 ± 0.189
FT4 [pmol/L] 62.5 ± 29.0 21.9 ± 17.5 16.4 ± 2.68
TSH [mIU/L] 0.0061 ± 0.00320 1.11 ± 0.930 2.18 ± 1.06
TRAb [IU/L] 18.3 ± 13.9 11.7 ± 10.6 0.873 ± 0.402
qRT-PCR — quantitative reverse transcription polymerase chain reaction; GD — Graves’ disease; NC — normal control; FT3 — free thriiodothyronine; FT4 — free 
tetraiodothyronine; TSH — thyroid-stimulating hormone; TRAb — thyrotropin receptor antibody
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Figure 1. P35mRNA and Ebi3mRNA expression in peripheral 
blood mononuclear cells (PBMCs). The expression of P35mRNA 
and Ebi3mRNA in new onset Graves’ disease (GD) and refractory 
GD were both higher than normal control (NC) [P35: new onset 
GD vs. NC (*p = 0.028), refractory GD vs. NC (**p = 0.031); 
Ebi3: newly onset GD vs. NC (#p = 0.039), refractory GD vs. 
NC (##p = 0.042)]. There was no difference in both P35 mRNA 
and Ebi3mRNA expression between remission GD and NC. 
Intra-group comparison found Ebi3mRNA expression was more 
elevated in new onset GD than in remission GD (###p = 0.030)
Figure 2. Serum IL-35 concentration among new onset Graves’ 
disease (GD), refractory GD, and normal control (NC) have 
no statistical difference
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Table III. Demographic and clinical data of participants — participants for ELISA
Characteristics New onset GD Refractory GD NC
Gender
Male 0 3 1
Female 9 7 6
Age [years] 38.8 ± 15.3 40.3 ± 14.2 31.0 ± 8.50
Thyroid function
FT3 [pmol/L] 24.0 ± 14.0 7.26 ± 4.62
FT4 [pmol/L] 57.3 ± 28.4 17.6 ± 6.90
TSH [mIU/L] 0.00563 ± 0.00177 0.906 ± 0.873
TRAb [IU/L] 16.8 ± 9.05 13.9 ± 12.8
IL-35 [ng/mL] 8.43 ± 5.88 7.40 ± 4.66 5.75 ± 4.27
ELISA — enzyme linked immunosorbent assay; GD — Graves’ disease; NC — normal control; FT3 — free thriiodothyronine; FT4 — free tetraiodothyronine;  
TSH — thyroid-stimulating hormone; TRAb — thyrotropin receptor antibody; IL-35 — interleukin 35
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Discussion
Although the fundamental pathogenesis of GD re-
mains unknown, it is generally believed to be a mul-
tifactorial disease caused by environmental factors 
and genetic susceptibility. The interactions between 
them lead to the initiation of immune disequilibrium 
including cell-mediated and humoral immune dys-
functions. As for cell-mediated immune dysfunction, 
CD4+T cell subsets are mainly studied cells. Among 
them, induced Treg (iTreg) cells are divided into Th3 
(TGF-b-induced-iTreg), Tr1 (IL-10-induced-iTreg), and 
iTr35 (IL-35-induced-iTreg), according to their genera-
tion mechanisms [23]. iTr35 is a relatively newly de-
fined iTreg subset, which has a highly restricted CD4+/
/Foxp3−/Ebi3+/P35+/IL10−/TGF-b− genetic signature 
[10]. iTr35 can suppress immune response through 
the suppression of Th17 proliferation and expansion 
of Treg through secretion of IL-35 [10]. Th17/Treg cell 
imbalance is a well-known cell-mediated immune 
dysfunction mechanism of GD [4, 24], which raises 
the possibility that IL-35 may play a partial role in its 
pathogenesis. 
In the present study, inter-group comparison 
showed that the P35 and Ebi3 mRNA expression levels 
of new onset and refractory GD were both significantly 
higher than controls. While there was no difference 
between remission GD and controls. These data sug-
gest that IL-35 might participate in the pathogenesis of 
GD. IL-35 is well documented as an anti-inflammatory 
cytokine in multiple autoimmune diseases; however, 
as its subunit, P35 is found to be a pro-inflammatory 
factor [25] or just act as a ligand [26]. Characterisation 
of Ebi3 reveals that it has a dual role, having either 
pro-inflammatory or anti-inflammatory properties 
[27]. Therefore, it is Ebi3 that may mainly exert the im-
munological function of IL-35 [16]. The Ebi3mRNA ex-
pression, but not P35mRNA, in new onset GD was sig-
nificantly higher than remission GD in our subsequent 
intra-group comparison. This might further verify the 
hypothesis above and suggest that the Ebi3mRNA 
expression is related to the activity of GD and could be 
downregulated along with the remission of disease. 
Levels of IL-35 in approximately 70% of the participants 
were undetectable due to its low density in serum. This 
may be the reason why the IL-35 serum level was not 
fully consistent with its mRNA expression. Also, we 
could not exclude the possibility of post-transcriptional 
regulation of IL-35.
Variable studies have confirmed the immuno-
regulatory role of IL-35 in many other autoimmune 
diseases. In active SLE, serum IL-35 levels were 
significantly decreased and negatively correlated with 
the SLE disease activity parameters (SLEDAI) [18]. 
Similar results were found in IBD: serum IL-35 levels 
were significantly decreased in IBD patients and corre-
lated inversely with UC activity [19]. In MS, the serum 
levels of IL-35 in treated patients were significantly 
higher than those in the controls, but no significant 
difference between untreated MS patients and con-
trols was found [20]. Serum IL-35 levels were lower 
in the HT group when compared with the subclinical 
HT group and controls and inversely associated with 
clinic parameters [17]. However, our study revealed 
opposite results: upregulation of IL-35 in GD. As we 
know, IL-35 is an anti-inflammatory cytokine; thus, we 
speculated that its elevation might reflect a compensa-
tional response or protective mechanism. Besides, the 
immunopathogenesis of GD contains a complicated 
and multifactorial regulatory network; a single im-
munocyte or cytokine could not possibly explain its 
mechanism completely.
Conclusions
Our preliminary observations indicate for the first 
time that IL-35 may be involved in the pathogenesis of 
GD. Other studies of IL-35 expression and its role are 
mandatory for further elucidation of the pathogenesis 
of Graves’ disease.
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